OMALIZUMAB (Xolair) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires Anti-IgE prior-authorization documentation for OMALIZUMAB (Xolair): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Regence reviews OMALIZUMAB (Xolair) prior authorizations against its medical policy for Anti-IgE. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Anti-IgE
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
OMALIZUMAB (Xolair)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- IgE level thresholds (30-1500 IU/mL) for asthma indication
- Indication restriction (asthma vs CIU vs nasal polyps vs food allergy)
- Step therapy requiring trial of inhaled corticosteroid + LABA first
Brand: Xolair. Anti-IgE monoclonal antibody. FDA-approved for moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria, nasal polyps, and food allergy IgE-mediated (February 2024 — first FDA-approved drug to reduce allergic reactions to multiple foods).
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
How Regence approaches Biologic drugs (mAbs and biosimilars) PAs
For OMALIZUMAB (XOLAIR), check whether the current Regence Biologic drugs (mAbs and biosimilars) policy cites step therapy via prime therapeutics or specialty drug pa. Pharmacy-benefit review for OMALIZUMAB (XOLAIR) at Regence is routed through Prime Therapeutics. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Regence; if denied, use the filing date and route printed on that denial notice. Regence's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Regence is domiciled in OR, so unresolved appeals escalate to the OR insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus an applicable, current clinical source supporting OMALIZUMAB (Xolair)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Regence denial on DenialHelp.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for OMALIZUMAB (Xolair) prior auth?
Regence's typical PA packet for OMALIZUMAB (Xolair): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Anti-IgE, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OMALIZUMAB (Xolair) at Regence?
Preparation scenarios to check against the current notice and policy include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. These are not measured frequency claims. For OMALIZUMAB (Xolair), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Regence typically require before approving OMALIZUMAB (XOLAIR)?
Regence's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For OMALIZUMAB (XOLAIR), attach the specific disease-activity instrument Regence accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Regence fully-insured policies sits with the OR insurance department.
How do I prep for a peer-to-peer with Regence on OMALIZUMAB (Xolair)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OMALIZUMAB (Xolair) PA packet
Open ApprovalHelp — generate a OMALIZUMAB (Xolair) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com